KR20240005122A - 아세트아미노펜 및 설포알킬 에테르 사이클로덱스트린을 함유하는 제형 - Google Patents
아세트아미노펜 및 설포알킬 에테르 사이클로덱스트린을 함유하는 제형 Download PDFInfo
- Publication number
- KR20240005122A KR20240005122A KR1020237043884A KR20237043884A KR20240005122A KR 20240005122 A KR20240005122 A KR 20240005122A KR 1020237043884 A KR1020237043884 A KR 1020237043884A KR 20237043884 A KR20237043884 A KR 20237043884A KR 20240005122 A KR20240005122 A KR 20240005122A
- Authority
- KR
- South Korea
- Prior art keywords
- formulation
- acetaminophen
- ppm
- captisol
- cyclodextrin
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
- A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/40—Cyclodextrins; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
- A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pain & Pain Management (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Dermatology (AREA)
- Rheumatology (AREA)
- Inorganic Chemistry (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662395794P | 2016-09-16 | 2016-09-16 | |
| US62/395,794 | 2016-09-16 | ||
| KR1020197010786A KR20190065296A (ko) | 2016-09-16 | 2017-09-15 | 아세트아미노펜 및 설포알킬 에테르 사이클로덱스트린을 함유하는 제형 |
| PCT/US2017/051919 WO2018053358A1 (en) | 2016-09-16 | 2017-09-15 | Formulations containing acetaminophen and sulfoalkyl ether cyclodextrin |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020197010786A Division KR20190065296A (ko) | 2016-09-16 | 2017-09-15 | 아세트아미노펜 및 설포알킬 에테르 사이클로덱스트린을 함유하는 제형 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| KR20240005122A true KR20240005122A (ko) | 2024-01-11 |
Family
ID=61619250
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020237043884A Ceased KR20240005122A (ko) | 2016-09-16 | 2017-09-15 | 아세트아미노펜 및 설포알킬 에테르 사이클로덱스트린을 함유하는 제형 |
| KR1020197010786A Ceased KR20190065296A (ko) | 2016-09-16 | 2017-09-15 | 아세트아미노펜 및 설포알킬 에테르 사이클로덱스트린을 함유하는 제형 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020197010786A Ceased KR20190065296A (ko) | 2016-09-16 | 2017-09-15 | 아세트아미노펜 및 설포알킬 에테르 사이클로덱스트린을 함유하는 제형 |
Country Status (8)
| Country | Link |
|---|---|
| US (2) | US12527755B2 (https=) |
| EP (1) | EP3512511A4 (https=) |
| JP (3) | JP7181185B2 (https=) |
| KR (2) | KR20240005122A (https=) |
| CN (2) | CN116869983A (https=) |
| AU (3) | AU2017326519B2 (https=) |
| MX (2) | MX2019002976A (https=) |
| WO (1) | WO2018053358A1 (https=) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2023224112A1 (ja) * | 2022-05-20 | 2023-11-23 | 株式会社ダイセル | 液状医薬組成物 |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2751875B1 (fr) | 1996-08-05 | 1998-12-24 | Scr Newpharm | Nouvelles formulations liquides stables a base de paracetamol et leur mode de preparation |
| RU2173172C2 (ru) | 1997-05-05 | 2001-09-10 | Сайдекс Инк. | Твердые фармацевтические препараты, содержащие физическую смесь сульфоалкилового эфира циклодекстрина и терапевтического агента |
| US6046177A (en) * | 1997-05-05 | 2000-04-04 | Cydex, Inc. | Sulfoalkyl ether cyclodextrin based controlled release solid pharmaceutical formulations |
| US7034013B2 (en) | 2001-03-20 | 2006-04-25 | Cydex, Inc. | Formulations containing propofol and a sulfoalkyl ether cyclodextrin |
| US6869939B2 (en) | 2002-05-04 | 2005-03-22 | Cydex, Inc. | Formulations containing amiodarone and sulfoalkyl ether cyclodextrin |
| WO2009098716A2 (en) | 2008-01-17 | 2009-08-13 | Aptuit Laurus Private Limited | Stable pharmaceutical aqueous compositions |
| DK2277546T3 (en) | 2009-07-23 | 2015-08-17 | Uni Pharma Kleon Tsetis Pharmaceutical Lab S A | Stable, ready to use, injectable paracetamol formulation |
| PH12013500477A1 (en) | 2010-09-13 | 2018-01-17 | Bev Rx Inc | Aqueous drug delivery system comprising off-flavor masking agent |
| EP2508558B1 (en) | 2011-04-07 | 2014-05-21 | Borealis AG | Silane crosslinkable polymer composition |
| RU2615385C2 (ru) | 2012-02-28 | 2017-04-04 | Сидекс Фармасьютикалс, Инк. | Композиции алкилированного циклодекстрина и способы их получения и применения |
| CN102871994B (zh) | 2012-09-29 | 2015-07-29 | 中国科学院大连化学物理研究所 | 氟比洛芬对乙酰氨基酚酯环糊精包合物及其制备方法 |
| BR102014005885B1 (pt) | 2014-03-13 | 2021-04-13 | Biotec Biológica Indústria Farmacêutica Ltda E.P.P | Formulação farmacêutica líquida injetável estável de paracetamol em bolsa plástica pronta para uso |
| EP4098282A1 (en) * | 2016-02-04 | 2022-12-07 | Czap Research And Development, LLC | Controlled-release and stratified cyclodextrin inclusion complex vehicles |
-
2017
- 2017-09-15 US US16/333,576 patent/US12527755B2/en active Active
- 2017-09-15 CN CN202310814285.1A patent/CN116869983A/zh active Pending
- 2017-09-15 CN CN201780071033.7A patent/CN110167543A/zh active Pending
- 2017-09-15 EP EP17851668.8A patent/EP3512511A4/en active Pending
- 2017-09-15 JP JP2019514754A patent/JP7181185B2/ja active Active
- 2017-09-15 KR KR1020237043884A patent/KR20240005122A/ko not_active Ceased
- 2017-09-15 WO PCT/US2017/051919 patent/WO2018053358A1/en not_active Ceased
- 2017-09-15 AU AU2017326519A patent/AU2017326519B2/en active Active
- 2017-09-15 KR KR1020197010786A patent/KR20190065296A/ko not_active Ceased
- 2017-09-15 MX MX2019002976A patent/MX2019002976A/es unknown
-
2019
- 2019-03-14 MX MX2023003761A patent/MX2023003761A/es unknown
-
2022
- 2022-08-05 JP JP2022125300A patent/JP2022140780A/ja active Pending
-
2023
- 2023-06-13 AU AU2023203660A patent/AU2023203660A1/en not_active Abandoned
-
2024
- 2024-02-28 JP JP2024028183A patent/JP2024051102A/ja active Pending
-
2025
- 2025-06-06 AU AU2025204233A patent/AU2025204233A1/en active Pending
- 2025-12-26 US US19/433,359 patent/US20260115157A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| CN110167543A (zh) | 2019-08-23 |
| WO2018053358A1 (en) | 2018-03-22 |
| EP3512511A4 (en) | 2020-05-20 |
| US12527755B2 (en) | 2026-01-20 |
| EP3512511A1 (en) | 2019-07-24 |
| AU2025204233A1 (en) | 2025-06-26 |
| AU2023203660A1 (en) | 2023-07-06 |
| AU2017326519B2 (en) | 2023-03-16 |
| MX2023003761A (es) | 2023-04-26 |
| US20260115157A1 (en) | 2026-04-30 |
| CN116869983A (zh) | 2023-10-13 |
| JP7181185B2 (ja) | 2022-11-30 |
| KR20190065296A (ko) | 2019-06-11 |
| RU2019107764A3 (https=) | 2021-01-15 |
| JP2024051102A (ja) | 2024-04-10 |
| US20190255000A1 (en) | 2019-08-22 |
| CA3036989A1 (en) | 2018-03-22 |
| AU2017326519A1 (en) | 2019-04-11 |
| RU2019107764A (ru) | 2020-10-16 |
| MX2019002976A (es) | 2019-07-10 |
| JP2022140780A (ja) | 2022-09-27 |
| JP2019532927A (ja) | 2019-11-14 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR101767689B1 (ko) | 항미생물 조성물 | |
| US20260115157A1 (en) | Formulations containing acetaminophen and sulfoalkyl ether cyclodextrin | |
| KR20180119610A (ko) | 즉시 사용가능한 케토로락 제제 | |
| KR101156325B1 (ko) | 방사선 보호 α,β 불포화 아릴설폰 제형 | |
| US20230255919A1 (en) | Composition containing cyclodextrin and busulfan | |
| RU2772384C9 (ru) | Составы, содержащие ацетаминофен и сульфоалкиловый эфир циклодекстрина | |
| RU2772384C2 (ru) | Составы, содержащие ацетаминофен и сульфоалкиловый эфир циклодекстрина | |
| CA3036989C (en) | Formulations containing acetaminophen and sulfoalkyl ether cyclodextrin | |
| RU2787621C2 (ru) | Композиция, содержащая циклодекстрин и бусульфан | |
| US20170368055A1 (en) | Methods for treating infections | |
| HK1213821B (en) | Antimicrobial compositions |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A107 | Divisional application of patent | ||
| PA0104 | Divisional application for international application |
St.27 status event code: A-0-1-A10-A18-div-PA0104 St.27 status event code: A-0-1-A10-A16-div-PA0104 |
|
| PG1501 | Laying open of application |
St.27 status event code: A-1-1-Q10-Q12-nap-PG1501 |
|
| A201 | Request for examination | ||
| PA0201 | Request for examination |
St.27 status event code: A-1-2-D10-D11-exm-PA0201 |
|
| E902 | Notification of reason for refusal | ||
| PE0902 | Notice of grounds for rejection |
St.27 status event code: A-1-2-D10-D21-exm-PE0902 |
|
| T11-X000 | Administrative time limit extension requested |
St.27 status event code: U-3-3-T10-T11-oth-X000 |
|
| T11-X000 | Administrative time limit extension requested |
St.27 status event code: U-3-3-T10-T11-oth-X000 |
|
| P11-X000 | Amendment of application requested |
St.27 status event code: A-2-2-P10-P11-nap-X000 |
|
| R18 | Changes to party contact information recorded |
Free format text: ST27 STATUS EVENT CODE: A-3-3-R10-R18-OTH-X000 (AS PROVIDED BY THE NATIONAL OFFICE) |
|
| R18-X000 | Changes to party contact information recorded |
St.27 status event code: A-3-3-R10-R18-oth-X000 |
|
| B15 | Application refused following examination |
Free format text: ST27 STATUS EVENT CODE: N-2-6-B10-B15-EXM-PE0601 (AS PROVIDED BY THE NATIONAL OFFICE) |
|
| PE0601 | Decision on rejection of patent |
St.27 status event code: N-2-6-B10-B15-exm-PE0601 |
|
| T11 | Administrative time limit extension requested |
Free format text: ST27 STATUS EVENT CODE: U-3-3-T10-T11-OTH-X000 (AS PROVIDED BY THE NATIONAL OFFICE) |
|
| T11-X000 | Administrative time limit extension requested |
St.27 status event code: U-3-3-T10-T11-oth-X000 |
|
| T13-X000 | Administrative time limit extension granted |
St.27 status event code: U-3-3-T10-T13-oth-X000 |